| 摘要 |
The process comprises (a) forming 1/ alpha -acetoxy-11 beta -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dione-3,20-dione (VA-2914) isopropanol hemisolvate crystals by dissolving in isopropanol and subsequently crystallising; (b) separating the VA-2914 isopropanol hemisolvate crystals; and (c) converting said VA-2914 isopropanol hemisolvate into VA-2914. The VA-2914 compound is a steroid with anti-progestational and anti-glucocorticoid activity, useful in therapeutic and contraceptive gynaecological indications and in treating Cushing's syndrome and glaucoma. |
